Trevi Therapeutics to Present Phase 2 Data on Chronic Cough Treatment at ERS Congress 2026
Event summary
- Trevi Therapeutics will present Phase 2b CORAL and Phase 2a RIVER trial data at ERS Congress 2026 in Barcelona.
- Oral presentation on IPF-related chronic cough by Professor Marlies Wijsenbeek on September 7.
- Poster presentation on refractory chronic cough by Dr. Imran Satia on September 7.
- Trials evaluated nalbuphine ER's efficacy in reducing cough frequency and improving quality of life.
The big picture
Trevi Therapeutics is advancing its investigational therapy Haduvio (oral nalbuphine ER) for chronic cough in IPF and RCC, areas with no FDA-approved treatments. The upcoming presentations at ERS Congress 2026 will provide critical insights into the drug's efficacy and quality-of-life improvements, potentially shaping its future development and commercialization strategy. With a substantial patient population suffering from uncontrolled chronic cough, successful outcomes could position Trevi as a key player in this high-need market.
What we're watching
- Clinical Efficacy
- How the Phase 2 data will position nalbuphine ER against competitors in the chronic cough treatment space.
- Regulatory Pathway
- Whether the positive trial results will accelerate Trevi's plans for regulatory submissions.
- Market Potential
- The pace at which Trevi can address the significant unmet need in IPF and RCC patient populations.